Prot# CC-5013-DLC-001: A Phase 2/3 Mulitcenter, Randomized Open-Label Stuyd to Compare the Efficacy and Safety of Lenalidomide (Revlimid®) Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Project: Research project

Project Details

StatusFinished
Effective start/end date10/26/10 → 10/26/13

Funding

  • Celgene Corporation (CC-5013-DLC-001)